Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 4, 2001, Pages 351-361

  Park, Jai Wun ^a,b   Siekmeier, Ruidiger ^a,b   Lattke, Peter ^a   Merz, Mechthild ^c   Mix, Comnelia ^a   Schuiler, Stefan ^a   Jaross, Werner ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^c Department of Cardiology   (Germany)

Author keywords

Cholesterol; Cyclosporine A; Fluvastatin; Heart transplantation; HMG CoA reductase inhibitor; Lipoproteins

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN A; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART GRAFT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 0035710125     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600404     Document Type: Article

References (42)

1. Hyperlipidemia after heart transplantation
2. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation
3. Effects of cyclosporine therapy on plasma lipoprotein levels
4. Hyperlipidemia and transplantation: Etiologic factors and therapy
5. Hyperlipidemia after heart transplantation: Report of a 6-year experience with treatment recommendations
6. Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry
7. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
8. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine
9. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial
10. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors
11. Statins: Effective antiatherosclerotic therapy
12. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
13. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials
14. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
16. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
17. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation
18. Cholesterol-lowering therapy after heart transplantation: A 12-month randomized trial
19. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A
20. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients. An exercise provocation test
21. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
22. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
23. Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: Three-year experience
24. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia
25. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: Effects of treatment with pravastatin
26. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
27. Treatment of metabolic disorders with fluvastatin after renal transplantation
28. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine
29. The effects of pravastatin on hyperlipidemia in renal transplant recipients
30. Effect of pravastatin on renal transplant recipients treated with cyclosporine - 4-Year follow up
31. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors
32. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
33. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
34. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
35. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin
36. Clinically significant drug interactions with cyclosporin. An update
37. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
38. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC
39. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
40. Fluvastatin. A review of its pharmacology and use in the management of hypercholesterolemia